The American Thyroid Association guideline for medullary thyroid cancer sets out RET germline testing for every patient, the timing of prophylactic thyroidectomy in hereditary carriers by mutation risk, surgical extent, and systemic therapy for advanced disease.
Comprehensive guideline covering diagnosis and genetic testing, risk categories for RET mutations (highest, high, moderate) with recommended ages for prophylactic surgery, initial surgical management, postoperative calcitonin surveillance, management of persistent or recurrent disease, external radiotherapy and kinase inhibitors.
The medullary thyroid cancer page's approach to hereditary carriers and to surgery without radioactive iodine follows this guideline.